Biogen Valuation
| BIIB Stock | USD 185.45 8.69 4.92% |
At this time, the firm appears to be undervalued. Biogen Inc shows a prevailing Real Value of $201.74 per share. The current price of the firm is $185.45. Our model approximates the value of Biogen Inc from analyzing the firm fundamentals such as Current Valuation of 28.9 B, profit margin of 0.16 %, and Return On Equity of 0.0931 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Biogen's valuation include:
Price Book 1.4242 | Enterprise Value | Enterprise Value Ebitda 9.7554 | Price Sales 2.7028 | Forward PE 11.2613 |
Undervalued
Today
Please note that Biogen's price fluctuation is very steady at this time. Calculation of the real value of Biogen Inc is based on 3 months time horizon. Increasing Biogen's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Biogen is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Biogen Stock. However, Biogen's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 185.45 | Real 201.74 | Target 192.72 | Hype 185.87 | Naive 185.12 |
The real value of Biogen Stock, also known as its intrinsic value, is the underlying worth of Biogen Inc Company, which is reflected in its stock price. It is based on Biogen's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Biogen's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Biogen Inc helps investors to forecast how Biogen stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Biogen more accurately as focusing exclusively on Biogen's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Biogen's intrinsic value based on its ongoing forecasts of Biogen's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Biogen's closest peers. If more than one evaluation category is relevant for Biogen we suggest using both methods to arrive at a better estimate.
Biogen Cash |
|
Biogen Revenue by Product
Biogen Total Value Analysis
Biogen Inc is currently forecasted to have valuation of 28.9 B with market capitalization of 27.21 B, debt of 6.63 B, and cash on hands of 4.91 B. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Biogen fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
28.9 B | 27.21 B | 6.63 B | 4.91 B |
Biogen Investor Information
About 95.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.42. Some equities with similar Price to Book (P/B) outperform the market in the long run. Biogen Inc recorded earning per share (EPS) of 10.98. The entity had not issued any dividends in recent years. The firm had 3:1 split on the 18th of January 2001. Based on the analysis of Biogen's profitability, liquidity, and operating efficiency, Biogen Inc is doing better financially today then in previous quarter. It has a moderate odds of reporting better financial numbers in March.Biogen Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Biogen has an asset utilization ratio of 34.5 percent. This suggests that the Company is making $0.34 for each dollar of assets. An increasing asset utilization means that Biogen Inc is more efficient with each dollar of assets it utilizes for everyday operations.Biogen Profitability Analysis
Considering Biogen's profitability and operating efficiency indicators, Biogen Inc is performing exceptionally good at this time. It has a great odds to showcase excellent profitability results in March. Profitability indicators assess Biogen's ability to earn profits and add value for shareholders.Net Income | First Reported 1985-09-30 | Previous Quarter 634.8 M | Current Value 466.5 M | Quarterly Volatility 414.5 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.5 | 0.69 |
|
|
For Biogen profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Biogen Inc to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Biogen utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Biogen's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Biogen over time as well as its relative position and ranking within its peers.
Biogen Earnings per Share Projection vs Actual
The next projected EPS of Biogen is estimated to be 3.4538 with future projections ranging from a low of 2.83 to a high of 4.15. Biogen's most recent 12-month trailing earnings per share (EPS TTM) is at 10.98. Please be aware that the consensus of earnings estimates for Biogen Inc is based on EPS before non-recurring items and includes expenses related to employee stock options.Biogen Earnings Estimation Breakdown
The calculation of Biogen's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Biogen is estimated to be 3.4538 with the future projection ranging from a low of 2.83 to a high of 4.15. Please be aware that this consensus of annual earnings estimates for Biogen Inc is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
2.83 Lowest | Expected EPS | 4.15 Highest |
Biogen Earnings Projection Consensus
Suppose the current estimates of Biogen's value are higher than the current market price of the Biogen stock. In this case, investors may conclude that Biogen is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Biogen's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 35 | 85.82% | 0.0 | 3.4538 | 10.98 |
Biogen Ownership Allocation
Biogen holds a total of 146.7 Million outstanding shares. The majority of Biogen Inc outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Biogen Inc to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Biogen. Please pay attention to any change in the institutional holdings of Biogen Inc as this could imply that something significant has changed or is about to change at the company. On September 12, 2025, Representative Ro Khanna of US Congress acquired under $15k worth of Biogen Inc's common stock.Biogen Profitability Analysis
The company reported the previous year's revenue of 9.68 B. Net Income was 1.63 B with profit before overhead, payroll, taxes, and interest of 7.71 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Biogen's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Biogen and how it compares across the competition.
About Biogen Valuation
The stock valuation mechanism determines Biogen's current worth on a weekly basis. Our valuation model uses a comparative analysis of Biogen. We calculate exposure to Biogen's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Biogen's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 8.5 B | 8.9 B | |
| Pretax Profit Margin | 0.18 | 0.19 | |
| Operating Profit Margin | 0.23 | 0.24 | |
| Net Profit Margin | 0.15 | 0.16 | |
| Gross Profit Margin | 0.69 | 0.50 |
Biogen Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 145.9 M | |
| Quarterly Earnings Growth Y O Y | 0.192 | |
| Forward Price Earnings | 11.2613 |
Biogen Current Valuation Indicators
Valuation refers to the process of determining the present value of Biogen Inc and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Biogen we look at many different elements of the entity such as Biogen's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Biogen, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Biogen's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Biogen's worth.Complementary Tools for Biogen Stock analysis
When running Biogen's price analysis, check to measure Biogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biogen is operating at the current time. Most of Biogen's value examination focuses on studying past and present price action to predict the probability of Biogen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biogen's price. Additionally, you may evaluate how the addition of Biogen to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |